Boston Scientific (BSX)
NYSE:BSX
Want to see BSX full AI Analyst Report?
BSX Stock Chart & Stats
$64.23
$4.44(4.82%)
At close: 4:00 PM EST
$64.23
$4.44(4.82%)
Day’s Range― - ―
52-Week Range$47.35 - $109.50
Previous CloseN/A
Volume5.49M
Average Volume (3M)21.54M
Market Cap
$70.87B
Enterprise Value$81.31B
Total Cash (Recent Filing)$1.52B
Total Debt (Recent Filing)$11.03B
Price to Earnings (P/E)19.9
Beta0.68
Next Earnings
Jul 29, 2026EPS Estimate
0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.40
Shares Outstanding1,486,355,200
10 Day Avg. Volume24,441,202
30 Day Avg. Volume21,537,912
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)5.82
Price to Sales (P/S)7.03
P/FCF Ratio38.59
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue3.94
Enterprise Value/Gross Profit5.60
Enterprise Value/Ebitda17.07
Forecast
1Y Price Target
$81.64Price Target Upside27.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering27
EPS Forecast (FY)3.37
Revenue Forecast (FY)$21.64B
Bulls Say, Bears Say
Bulls Say
Scale & Margin ImprovementSustained multi-year revenue expansion and marked margin improvement indicate durable operational leverage. Larger scale supports R&D, commercial investment and pricing flexibility, improving returns on capital and making near-term shocks easier to absorb while enabling longer-term product development.
Cash Generation & LiquidityStrong absolute operating and free cash flow provides durable funding for capex, M&A and buybacks without immediate reliance on external financing. Even with modest conversion headwinds, multi-billion FCF supports strategic investments and preserves flexibility through economic cycles.
Strategic TAVR InvestmentThe MiRus stake and option to acquire a novel TAVR platform is a structural move into a high-growth segment. Access to a nickel-free, low-profile valve and an ongoing pivotal trial can materially expand structural heart addressable market and diversify durable revenue streams over coming years.
Bears Say
Meaningful Absolute DebtElevated absolute debt levels reduce financial flexibility if macro or industry funding costs rise. While leverage ratios improved, the substantial nominal debt stock can constrain capital deployment, limit downside protection in downturns, and raise refinancing risk over the medium term.
Free Cash Flow SofteningA recent FCF decline and below-1x cash conversion vs. net income suggest working-capital or timing pressures that could persist. This weakens the margin of safety for funding growth, acquisitions, or buybacks and makes capital allocation more sensitive to cyclical procedure volumes.
Product Disruptions & Margin HeadwindsProduct discontinuations and related inventory charges are structural risks: they erode gross margins, disrupt regional sales mixes, and can damage clinical confidence. These headwinds may persist while replacement products, regulatory responses, and inventory clean-up take multiple quarters to resolve.
Boston Scientific News
BSX FAQ
What was Boston Scientific’s price range in the past 12 months?
Boston Scientific lowest stock price was $47.35 and its highest was $109.50 in the past 12 months.
What is Boston Scientific’s market cap?
Boston Scientific’s market cap is $70.87B.
When is Boston Scientific’s upcoming earnings report date?
Boston Scientific’s upcoming earnings report date is Jul 29, 2026 which is in 55 days.
How were Boston Scientific’s earnings last quarter?
Boston Scientific released its earnings results on Apr 22, 2026. The company reported $0.8 earnings per share for the quarter, beating the consensus estimate of $0.788 by $0.012.
Is Boston Scientific overvalued?
According to Wall Street analysts Boston Scientific’s price is currently Undervalued.
Does Boston Scientific pay dividends?
Boston Scientific does not currently pay dividends.
What is Boston Scientific’s EPS estimate?
Boston Scientific’s EPS estimate is 0.83.
How many shares outstanding does Boston Scientific have?
Boston Scientific has 1,486,355,200 shares outstanding.
What happened to Boston Scientific’s price movement after its last earnings report?
Boston Scientific reported an EPS of $0.8 in its last earnings report, beating expectations of $0.788. Following the earnings report the stock price went up 8.989%.
Which hedge fund is a major shareholder of Boston Scientific?
Currently, no hedge funds are holding shares in BSX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Boston Scientific Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.64 (27.10% Upside)
$81.64 (27.10% Upside)
Blogger Sentiment
Bullish
BSX Sentiment 90%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 15.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $554.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Bearish
Bullish news 29%
Bearish news 71%
Bearish news 71%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.22%
12-Months-Change
Fundamentals
Return on Equity
14.82%
Trailing 12-Months
Asset Growth
10.49%
Trailing 12-Months
Company Description
Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
BSX Company Deck
BSX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a mixed picture: a strong Q1 with organic growth and EPS above guidance, meaningful product and regional momentum (notably in EP/PFA, WATCHMAN clinical data, Asia Pacific), and solid capital priorities (buyback, Penumbra deal). However, management lowered near-term guidance and flagged several material headwinds — weaker Urology, some EP share pressure, margin compression (gross margin down 100 bps) and operational disruptions (POLARx discontinuation and supply issues) — leading to a more cautious full-year outlook. The company emphasizes confidence in longer-term strategy and product pipeline while taking near-term actions to control costs and invest commercially.View all BSX earnings summariesBSX Revenue Breakdown
33.99% MedSurg
66.01% Cardiovascular
BSX Stock 12 Month Forecast
Average Price Target
$81.64
▲(27.10% Upside)
Technical Analysis
Abbott Laboratories
―
Edwards Lifesciences
―
Medtronic
―
Stryker
―
Zimmer Biomet Holdings
―
Ownership Overview
0.13% Insiders
24.84% Mutual Funds
20.65% Other Institutional Investors
32.71% Public Companies and Individual Investors